Research programme: estrogen receptor alpha modulator therapeutics and diagnostics - Shenogen Pharma

Drug Profile

Research programme: estrogen receptor alpha modulator therapeutics and diagnostics - Shenogen Pharma

Alternative Names: SNG 1153; SNG 8003; SNG 8023; SNG-8006; SNG-8033; SNG-8038

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shenogen Pharma
  • Class Diagnostic agents; Drug conjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action Estrogen receptor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Chronic myeloid leukaemia; Endometrial cancer; Lung cancer; Unspecified
  • Discontinued Osteoporosis

Most Recent Events

  • 18 Oct 2016 Discontinued for Osteoporosis in China (unspecified route) (Shenogen Pharma pipeline, October 2016)
  • 18 Oct 2016 Preclinical trials in Breast cancer in China (unspecified route) (Shenogen Pharma website, October 2016)
  • 18 Oct 2016 Preclinical trials in Endometrial cancer in China (unspecified route) (Shenogen Pharma website, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top